Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists

A compound of formula (I):

• wherein
• A is —O— or —NH—;
• R1 is selected from the group consisting of hydrogen, C1-7-alkoxy and halogen;
• R2 is selected from the group consisting of C2-7-alkyl, C2-7-alkenyl, halogen-C1-7-alkyl, C1-7-alkoxy-C1-7-alkyl, and benzyl;
• R3 is selected from the group consisting of hydrogen, C1-7-alkyl, hydroxy, C1-7-alkoxy, C2-7-alkenyloxy, hydroxy-C1-7-alkoxy, C1-7-alkoxy-C1-7-alkoxy, —O—C3-7-cycloalkyl, halogen, halogen-C1-7-alkyl, halogen-C1-7-alkoxy, —C(O)OR6, wherein R6 is C1-7-alkyl, amino, pyrrolyl, unsubstituted phenyl or phenyl substituted by one to three groups independently selected from C1-7-alkyl, halogen and C1-7-alkoxy;
• R4 is selected from the group consisting of hydrogen, hydroxy, C1-7-alkoxy, amino, nitro, hydroxy-C1-7-alkoxy, C1-7-alkoxy-C1-7-alkoxy, and —O-benzyl;
• or R3 and R4 are bonded to each other to form a ring together with the carbon atoms they are attached to and R3 and R4 together are —O—C(CH3)2—CH═CH—;
• R5 is selected from the group consisting of hydrogen, halogen and C1-7-alkoxy;
• G is selected from the groups
• wherein
• R7 and R11 are hydrogen;
• R8 and R10 independently from each other are hydrogen or —NH—C(O)—R25, wherein R25 is C1-7-alkyl;
• R9 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, halogen-C1-7-alkyl, cyano, —C(O)OR26, wherein R26 is hydrogen or C1-7-alkyl, —(CH2)m—S(O)2—NH—R27, wherein m is 0 or 1 and R27 is selected from C1-7-alkyl, unsubstituted heteroaryl and heteroaryl substituted by C1-7-alkyl;
• and
• —NH—S(O)2—R28, wherein R28 is C1-7-alkyl;
• or R8 and R9 are bonded to each other to form a ring together with the carbon atoms they are attached to and R8 and R9 together are —CH2—S(O)2—CH2—;
• R12 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen and amino;
• R13 is selected from the group consisting of hydrogen, C1-7-alkyl, halogen, halogen-C1-7-alkyl, cyano, nitro, phenyl, tetrazolyl, benzoimidazolyl, —COOR29, wherein R29 is hydrogen or C1-7-alkyl, hydroxy-C1-7-alkoxy, cyano-C1-7-alkoxy, —CONHR30, wherein R30 is selected from the group consisting of hydrogen, C1-7-alkyl, C3-7-cycloalkyl, hydroxy-C1-7-alkyl, C1-7-alkoxy-C1-7-alkyl, halogen-C1-7-alkyl, carboxy-C1-7-alkyl, —(CH2)n—NH—C(O)—R31, wherein n is 1 or 2 and R31 is C1-7-alkyl, —S(O)2—R33, wherein R33 is C1-7-alkyl, —O—S(O)2—R34, wherein R34 is C1-7-alkyl, and —CO-heterocyclyl, wherein heterocyclyl is a ring selected from pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, said ring being unsubstituted or substituted by a group selected from hydroxy, carboxy, carbamoyl and C1-7-alkanoyl;
• R14 is selected from the group consisting of hydrogen, C1-7-alkyl, C1-7-alkoxy, C1-7-alkoxy-C1-7-alkyl, cyano, carbamoyl, —COOR35, wherein R35 is hydrogen or C1-7-alkyl, halogen and halogen-C1-7-alkyl;
• R15 is selected from the group consisting of hydrogen, cyano, halogen and halogen-C1-7-alkyl;
• R16 and R18 are hydrogen;
• R17 is carbamoyl or —COOR32, wherein R32 is hydrogen or C1-7-alkyl;
• R19 is hydrogen or halogen;
• R20 is selected from the group consisting of hydrogen, C1-7-alkyl, C1-7-alkoxy, C1-7-alkoxy-C1-7-alkyl and halogen;
• R21, R22 and R23 independently from each other are hydrogen or halogen;
• R24 is hydrogen or C1-7-alkyl;
• and pharmaceutically acceptable salts thereof.